ST Pharm Signs 32.2 Billion KRW API Supply Contract with European Global Pharmaceutical Company
[Asia Economy Reporter Hyunseok Yoo] ST Pharm announced on the 22nd that it has signed a supply contract for clinical trial raw materials of oligonucleotide therapeutics worth 33.2 billion KRW with a global pharmaceutical company located in Europe.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This amount corresponds to 34.57% of recent sales, and the contract period is from today until January 11 of next year. The supply region is Switzerland.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
